The new three-year agreement grants HLH an exclusive licence to produce, package and commercialise a capsule containing Opti’s cholesterol-reducing LPLDL strain in Germany.
In order to maintain exclusivity in Germany, HLH will have to double its order volumes every year.
As part of the tie-up, HLH has also been granted a non-exclusive licence to produce, package and commercialise products containing LPLDL in Austria, Switzerland and the United Arab Emirates.
“We are pleased to announce this extension of terms and territory with HLH who is one of Europe's leading suppliers of probiotics to the pharmacy market,” said chief executive Stephen O’Hara.
“The agreement recognises the success of HLH in building sales of its LPLDL containing Lactobact brand in Germany and extends the terms and territory to support further sale growth.
“This is another step in extending the geographical reach of LPLDL as it builds recurring revenue streams and increases brand recognition and the value of its products.
“This is part of a strategy which allows OptiBiotix to present customised product solutions through its partners to consumer health, pharmaceutical and retail companies around the world.”